Results from the phase II TANZANITE clinical trial support further investigation of adding suprachoroidal triamcinolone acetonide to anti-vascular endothelial growth factor therapy for treatment-naïve retinal vein occlusion.
Although much progress has been made in treating retinal vein occlusions, much still needs to be done. Julia Haller, MD, described the four-step, evidence-based approach that she uses to treat these patients
Neovascular glaucoma is a potentially devastating ocular consequence of pathologic neovascularization of intraocular tissue. The symptoms include vision loss caused by both the underlying etiology (such as retinal vascular disease) as well as increased intraocular pressure (IOP), often accompanied by corneal edema, hyphema, or vitreous hemorrhage.
The advent of anti-vascular endothelial growth factor (VEGF) therapy has been a tremendous advance for the treatment of retinal vein occlusion (RVO), but many other opportunities exist, said Joan W. Miller, MD.
Based on findings from a series of clinical trials in recent years, pharmacotherapy has supplanted both laser photocoagulation and a watchful waiting approach as the first-line therapy for retinal vein occlusion.